Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Soon-Siong Teo

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
EXS|January 23, 2009
Mapping the epigenome--impact for toxicologyJennifer Marlowe, Soon-Siong Teo, Salah-Dine Chibout, et al.
Blood|May 6, 2006
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disordersRobert Kralovics, Soon-Siong Teo, Sai Li, et al.
Blood|May 6, 2003
Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disordersRobert Kralovics, Andreas S Buser, Soon-Siong Teo, et al.
The New England Journal of Medicine|April 29, 2005
A gain-of-function mutation of JAK2 in myeloproliferative disordersRobert Kralovics, Francesco Passamonti, Andreas S Buser, et al.
Haematologica|January 2, 2008
JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosisAnnette H Schmitt-Graeff, Soon-Siong Teo, Manfred Olschewski, et al.
Blood|March 17, 2007
Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutationAlexandre Theocharides, Marjorie Boissinot, François Girodon, et al.
Blood|August 6, 2005
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2Robert Kralovics, Soon-Siong Teo, Andreas S Buser, et al.
Plos One|April 2, 2011
Phenobarbital mediates an epigenetic switch at the constitutive androstane receptor (CAR) target gene Cyp2b10 in the liver of B6C3F1 miceHarri Lempiäinen, Arne Müller, Sarah Brasa, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
EXS|January 23, 2009
Mapping the epigenome--impact for toxicologyJennifer Marlowe, Soon-Siong Teo, Salah-Dine Chibout, et al.
Blood|May 6, 2006
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disordersRobert Kralovics, Soon-Siong Teo, Sai Li, et al.
Blood|May 6, 2003
Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disordersRobert Kralovics, Andreas S Buser, Soon-Siong Teo, et al.
The New England Journal of Medicine|April 29, 2005
A gain-of-function mutation of JAK2 in myeloproliferative disordersRobert Kralovics, Francesco Passamonti, Andreas S Buser, et al.
Haematologica|January 2, 2008
JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosisAnnette H Schmitt-Graeff, Soon-Siong Teo, Manfred Olschewski, et al.
Blood|March 17, 2007
Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutationAlexandre Theocharides, Marjorie Boissinot, François Girodon, et al.
Blood|August 6, 2005
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2Robert Kralovics, Soon-Siong Teo, Andreas S Buser, et al.
Plos One|April 2, 2011
Phenobarbital mediates an epigenetic switch at the constitutive androstane receptor (CAR) target gene Cyp2b10 in the liver of B6C3F1 miceHarri Lempiäinen, Arne Müller, Sarah Brasa, et al.
Pageof 1